Open AccessCytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study*
Author(s) -
Helena Stockmann,
Philipp Thelen,
Fabian Stroben,
Mareen Pigorsch,
Theresa Keller,
Alexander Krannich,
Claudia Spies,
Sascha Treskatsch,
Michele Ocken,
Julius Valentin Kunz,
Anne Krüger,
Dmytro Khadzhynov,
Susanne Kron,
Klemens Budde,
KaiUwe Eckardt,
Philipp Enghard,
Lukas Lehner
Publication year - 2022
Publication title -
critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.002
H-Index - 271
eISSN - 1530-0293
pISSN - 0090-3493
DOI - 10.1097/ccm.0000000000005493
Subject(s) - medicine , covid-19 , shock (circulatory) , intensive care medicine , randomized controlled trial , coronavirus infections , critically ill , virology , outbreak , disease , infectious disease (medical specialty)
To investigate the effect of extracorporeal cytokine reduction by CytoSorb (CytoSorbents, Monmouth Junction, NJ) on COVID-19-associated vasoplegic shock.